Martijn G. van Oijen
Papers
1
Total Citations
35
H-Index
1
About
Martijn G. van Oijen is a leading surgical oncologist whose research has reshaped the landscape of pancreatic surgery, with a particular focus on minimally invasive techniques and patient-centered outcomes. His landmark work, the LEOPARD randomized trial, fundamentally challenged the standard of care by demonstrating that minimally invasive distal pancreatectomy (MIDP) significantly improves short-term quality of life and accelerates functional recovery compared to open surgery for nonmalignant disease. His most-cited study, a long-term follow-up of the LEOPARD trial (2021, 35 citations), rigorously assessed whether these early benefits translate into sustained advantages, examining long-term quality of life, cosmetic satisfaction, and major complications. This work has been pivotal in driving the global adoption of MIDP, establishing van Oijen as a key figure in evidence-based surgical innovation. By rigorously prioritizing the patient’s lived experience alongside traditional surgical outcomes, his contributions have directly influenced clinical guidelines and improved postoperative recovery for countless patients. His research continues to define the future of minimally invasive pancreatic surgery.
Research Focus
Key Achievements
Top Papers
- 1